Neurological Disease

Chlothymol is a potent positive modulator of the GABA_A receptor subunit LGC-37, anticonvulsant, and antibacterial agent. Chlothymol inhibits Pentylenetetrazol-induced c-fos expression. Chlothymol inhibits the growth of Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA) strains, including LAC, with an MIC of 32 μg/mL. Chlorothymol has protective effects against epileptic seizures in various mouse models.

Mesaconitine (Standard) is the analytical standard of Mesaconitine. This product is intended for research and analytical applications. Mesaconitine is a nitric oxide synthase activator. Mesaconitine drives extracellular Na⁺ and Ca²⁺ influx into endothelial cells, increases intracellular Na⁺ and Ca²⁺ concentrations, and triggers nitric oxide release. Mesaconitine is applicable for pain-related research.

Cilansetron is a 5-HT3 receptor antagonist. Cilansetron can be used in studies of irritable bowel syndrome.

Cannabidiol monomethyl ether is a phytocannabinoid.

Norbinaltorphimine dihydrochloride (Standard) is the analytical standard of Norbinaltorphimine dihydrochloride (HY-100903). This product is intended for research and analytical applications. Norbinaltorphimine dihydrochloride (nor-Binaltorphimine dihydrochloride; nor-BNI dihydrochloride) is a selective, long-acting competitive antagonist of the κ-opioid receptor. Norbinaltorphimine dihydrochloride blocks κ-opioid receptor-mediated analgesic effects, and inhibits butorphanol-induced changes in κ-opioid receptor binding kinetics, desensitization and down-regulation. Norbinaltorphimine dihydrochloride suppresses specific opioid withdrawal symptoms, precipitates withdrawal behaviors in butorphanol-dependent rats, and serves as a molecular probe for studying κ-opioid receptor-agonist interactions. Norbinaltorphimine dihydrochloride is applicable to research related to neurological disorders such as pain.

LY 379196 is a PKC-β inhibitor (IC₅₀: 50 nM and 30 nM for PKC βI and βII respectively). LY 379196 inhibits the VEGF, IGF-1 and bFGF-induced proliferation of bovine retinal microvascular endothelial cells (BREC). LY 379196 is an antiproliferatory agentfor proliferative retinopathy.

(tert-Butoxycarbonyl)-DL-glutamine (Compound 2I) is a tert-butoxycarbonyl-protected glutamine derivative. (tert-Butoxycarbonyl)-DL-glutamine can be used for the synthesis of N-BOC-L-glutamine esters and Apocynin (HY-N0088). (tert-Butoxycarbonyl)-DL-glutamine is applicable to the research of retinal degenerative diseases.

Ipidacrine (Standard) is the analytical reference standard of Ipidacrine. This product is used for research and analytical applications. Ipidacrine is orally active and blood-brain-barrier-penetrant AChE and BuChE inhibitors with IC₅₀ values of 1 μM and 1.9 μM, respectively, which is also a partial agonist of M2-cholinergic receptors and a reversible cholinesterase inhibitor. Ipidacrine has a stimulating effect on neuromuscular transmission and excitation along the nerve fibres with a moderately anti-pain effect. Ipidacrine is an aminopyridines and is structurally similar to Tacrine (HY-111338). Ipidacrine is effective in various amnesia models, improves erectile function and inhibits K⁺ and Na⁺-channels in the neuronal membrane in diabetic rats. Ipidacrine is promising for research of Alzheimer’s disease, ischaemic stroke, idiopathic neuropathy of the facial nerve, diabetes mellitus-induced erectile dysfunction and other deficits in central or peripheral cholinergic deseases.

6',7'-Epoxy cannabigerol is a phytocannabinoid metabolite.

NMDA receptor modulator 8 (Compound 3-6) is a modulator for NMDA receptor, with 50%-100% potentiation of NMDA receptor at 10 μM.

PGL-135 is a blood-brain barrier-permeable Huntingtin aggregation inhibitor. PGL-135 is applicable to research related to Huntington's disease.

AC-4-248 is an atypical non-competitive dopamine transporter (DAT) inhibitor and reduces the potency of cocaine to inhibit DAT. AC-4-248 is a non-selective inhibitor of SLC6 transporters with IC₅₀ values for hDAT, hSERT, and hNET of 45.5 μM, 96.2 μM, and 250 μM, respectively.

BI-6C9 (Standard) is the analytical standard of BI-6C9 (HY-103661). This product is intended for research and analytical applications. BI-6C9 is a highly specific BH3 interacting domain (Bid) inhibitor, which prevents mitochondrial outer membrane potential (MOMP) and mitochondrial fission, and protects the cells from mitochondrial apoptosis inducing factor (AIF) release and caspase-independent cell death in neurons.

NAB2 (Standard) is the analytical standard of NAB2 (HY-110174). This product is intended for research and analytical applications. NAB2 is a neuroprotectant that targets the small GTPase Rab1a. NAB2 selectively binds to the GDP-bound form of Rab1a and protects multiple cell types from α-synuclein toxicity by increasing Rab1a expression. Rab1a regulates ER-to-Golgi trafficK_ing and mediates endosomal trafficK_ing events of the E3 ubiquitin ligase Rsp5/Nedd4. NAB2 stimulates ubiquitination of related proteins in a Nedd4-dependent manner and rescues α-synuclein-associated trafficK_ing defects associated with early-onset ParK_inson's disease.

Granisetron-d₆ (Hydrochloride) (BRL 43694A-d₆) is deuterium labeled Granisetron (Hydrochloride). Granisetron (Hydrochloride) (BRL 43694A) is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy.

Cevimeline (hydrochloride hemihydrate) (Standard) is the analytical standard of Cevimeline (hydrochloride hemihydrate). This product is intended for research and analytical applications. Cevimeline hydrochloride hemihydrate (SNI-2011) is a quinuclidine derivative of acetylcholine and a selective and orally active muscarinic M1 and M3 receptor agonist. Cevimeline hydrochloride hemihydrate stimulates secretion by the salivary glands and can be used as a sialogogue for xerostomia. Cevimeline hydrochloride hemihydrate can cross the blood-brain barrier (BBB).

ML218 (Standard) is the analytical standard of ML218 (HY-103309). This product is intended for research and analytical applications. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC₅₀s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier.

PSB-06126 (Standard) is the analytical standard of PSB-06126 (HY-103263). This product is intended for research and analytical applications. PSB-06126 is a selective nucleoside triphosphate diphosphohydrolase (NTPDase) inhibitor, with the K_i values of 0.33 μM for rat NTPDase 1, 19.1 μM for NTPDase 2 and 2.22 μM for NTPDase 3, respectively. PSB-06126 acts on human NTPDase 3 with an IC₅₀ value of 7.76 μM and a K_i value of 4.39 μM.

N-(1-Phenethyl-4-piperidyl)-N-phenethylpropanamide hydrochloride is structurally similar to known opioids.

Triethylcholine iodide is a choline acetyltransferase inhibitor and a regulator of the acetylcholine synthesis pathway. Triethylcholine iodide inhibits acetylcholine synthesis in brain tissues and blocks neuromuscular and autonomic ganglionic transmission. Triethylcholine iodide exerts weak curare-like effects at extremely high concentrations. Triethylcholine iodide elevates the pentylenetetrazol seizure threshold, alters electroencephalogram patterns in Felis catus, but does not affect the maximal electroshock seizure threshold in Oryctolagus cuniculus. Triethylcholine iodide can be used in seizure-related research.